Aduro Biotech, Inc. (NASDAQ:ADRO) Files An 8-K Other Events
Item8.01
| Other Events |
Attached hereto as Exhibit 99.1 is an investor presentation that
Aduro Biotech, Inc. plans to present during the 35th Annual J.P. Morgan Healthcare
Conference on January9, 2017.
Item9.01 |
Financial Statements and Exhibits |
(d) |
Exhibits. |
|
|
|
|
| 99.1 | Aduro Biotech, Inc. Investor Presentation. |
About Aduro Biotech, Inc. (NASDAQ:ADRO)
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development. Aduro Biotech, Inc. (NASDAQ:ADRO) Recent Trading Information
Aduro Biotech, Inc. (NASDAQ:ADRO) closed its last trading session up +0.10 at 12.00 with 129,971 shares trading hands.
